{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:58Z","timestamp":1753892038937,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>There is no standard treatment for stage III lung cancer due to its low surgical resection rate, and improving PFS and survival of patients with III NSCLC has become an urgent challenge in clinical treatment. For EGFR mutation-positive patients, targeted therapy has the remarkable feature of high efficiency and low toxicity compared with first-line standard chemotherapy, and targeted neoadjuvant therapy needs to be further explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We report 3 diagnosed cases of locally advanced unresectable NSCLC with EGFR-sensitive mutations who first received 1\u20132 cycles of preoperative chemotherapy neoadjuvant therapy and were treated with 110 mg daily of 3rd-generation EGFR-TKI aumolertinib instead because of poor efficacy or safety intolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>After 2 cycles of aumolertinib treatment, all 3 patients achieved symptomatic remission and significant tumor size reduction and achieved downstaging to allow surgical treatment. No additional operative difficulties were added during the surgery. They continued to receive adjuvant therapy with the original dose of aumolertinib after surgical treatment, and no evidence of tumor recurrence was found until the most recent imaging examination. In addition, the course of neoadjuvant and adjuvant therapy was free of serious adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Perioperative treatment of these three cases of locally advanced unresectable NSCLC with EGFR-sensitive mutations with the third-generation EGFR-TKI aumolertinib showed significant efficacy and excellent safety and may be a new option for targeted therapy in the perioperative period.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.872225","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:50:00Z","timestamp":1648630200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series"],"prefix":"10.3389","volume":"12","author":[{"given":"Shao","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wanwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Zhaozhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xie","family":"Yuewu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Shencun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.02.007","article-title":"Stage IIIA-N2 NSCLC: A Review of its Treatment Approaches and Future Developments","volume":"65","author":"van Meerbeeck","year":"2009","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.47","article-title":"Optimal Managements of Stage IIIA (N2) Non-Small Cell Lung Cancer Patients: A Population-Based Survival Analysis","volume":"9","author":"Pang","year":"2017","journal-title":"J Thorac Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative Chemotherapy for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Participant Data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1685","article-title":"Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial","volume":"28","author":"Pisters","year":"2010","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1019\/200720130","article-title":"Preoperative Chemotherapy in Non-Small Cell Lung Cancer: Advantages, Disadvantages, Level of Evidence","volume":"24","author":"Depierre","year":"2007","journal-title":"Rev Mal Respir"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2826","article-title":"Induction Chemoradiation and Surgical Resection for Superior Sulcus Non-Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"25","author":"Rusch","year":"2007","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu504","article-title":"Neoadjuvant Chemoradiation and Surgery Improves Survival Outcomes Compared With Definitive Chemoradiation in the Treatment of Stage IIIA N2 Non-Small-Cell Lung Cancer","volume":"48","author":"Darling","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.01.078","article-title":"Improved Results of Induction Chemoradiation Before Surgical Intervention for Selected Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer","volume":"134","author":"Uy","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin\/Paclitaxel in Clinically Selected Patients With Advanced non-Small-Cell Lung Cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib Versus Cisplatin Plus Gemcitabine for First-Line Treatment of Asian Patients With Advanced Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (LUX-Lung 6): An Open-Label, Randomised Phase 3 Trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00586-x","article-title":"Aumolertinib Is Effective in NSCLC","volume":"19","author":"Romero","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9013","article-title":"Randomized Phase III Trial of Aumolertinib (HS-10296, Au) Versus Gefitinib (G) as First-Line Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Exon 19 Del or L858R Mutations (EGFRm)","volume":"39","author":"Lu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II Study of Biomarker-Guided Neoadjuvant Treatment Strategy for IIIA-N2 Non-Small Cell Lung Cancer Based on Epidermal Growth Factor Receptor Mutation Status","volume":"8","author":"Zhong","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.10.020","article-title":"Histopathological and Immunohistochemical Features Associated With Clinical Response to Neoadjuvant Gefitinib Therapy in Early Stage Non-Small Cell Lung Cancer","volume":"76","author":"Lara-Guerra","year":"2012","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2010.06.035","article-title":"Salvage Surgery for Advanced Non-Small Cell Lung Cancer After Response to Gefitinib","volume":"140","author":"Hishida","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage non-Small-Cell Lung Cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2019.09.076","article-title":"Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer","volume":"109","author":"Rice","year":"2020","journal-title":"Ann Thorac Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.872225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T08:50:04Z","timestamp":1648630204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.872225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":22,"alternative-id":["10.3389\/fonc.2022.872225"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.872225","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"article-number":"872225"}}